Jane Leong Vice President(Medical Affairs, Asia Pacific), Moderna

Keynote : Bringing pandemic to endemic, robust mRNA platform next targeting cancer & rare diseases

- Global Medical Influenza Portfolio Lead, Seqirus
- VP Head of Scientific Affairs, bioCSL
- Melbourne Business School
- University of Melbourne

Seng Ho Jeon CEO, Daewoong Pharmaceutical

Bio trend ① : Daewoong Pharmaceutical Innovative Drug Development Keyword: R&D Platform & Open Collaboration

- Dieector, Global Business Development, Daewoong Pharmaceutical
- Director, The Pharmaceutical Society of Korea
- Director, Korea Drug Research Association
- MBA, Aalto University School of Business
- College of Pharmacy, Seoul National University

Rosa(Heejung) Kim R&D Scientific and Clinical Alliance Lead Director(Asia), AstraZeneca

Bio trend ② : Hope to cure incurable diseases…How far can ‘bispecific antibody’ reach?

- Associate Director, Asia alliances, AstraZeneca
- Medical Science & Operations manager, Takeda
- MSL Manager, Mundipharma
- Novartis
- Masters inClinical Research Design and Evaluation, Sungkyunkwan University
- Parmacy, Kyung Hee University

Sang Hoon Lee CEO, ABLBio

Bio trend ② : Hope to cure incurable diseases…How far can ‘bispecific antibody’ reach?

- Co-established PharmAbcine
- Vice President, Hanwha Chemical
- Ph.D in Developmental Biology, Ohio State University
- B.S. in Biological Education, Seoul National University

Mahn Soon Hwang(Chair) CEO, Korea Investment Partners

Discussion : Intensifying drug platform competition…Where are the promising investment destinations?

- Chairman, New Industry Organization for Investment
- Senior Vice President, Chemon
- Principal, Korea Biotech Investment Corporation
- Senior Researcher, Yuhan Pharmaceutical
- B.S., M.S. in Pharmacy, Seoul National University

Lambert Chanwoo Kuk(Participants) Group Head, KB investment

Discussion : Intensifying drug platform competition…Where are the promising investment destinations?

- KB Investment Head of Life Science and Healthcare Division, Senior Managing Director
- Samsung Medical Center, Center for Future Medicine
- IQViA Corporate Development Senior Specialist
- KPMG Healthcare Consulting Division
- M.S. in Healthcare Policy and Management, Carnegie Mellon University
- Indiana University, Bloomington

Seung Woo Lee(Participants) Executive Director, Devsisters Ventures

Discussion : Intensifying drug platform competition…Where are the promising investment destinations?

- Visiting Professor, Yonsei University College of Medicine
- Investment Head of Biohealthcare Division, Director, Bluepoint Partners
- Head of Clinical Development, Director, Ybrain, Inc.
- College of Medicine, Yonsei University

Hyun Woo Park(Participants) Investment manager, Timefolio Asset Management

Discussion : Intensifying drug platform competition…Where are the promising investment destinations?

- Project Leader, Portfolio Management Division, SK Holdings
- B.S. in Animal Science and Biotechnology, Seoul National University

James Choi Executive VP, Chief Information and Marketing Officer at Samsung Biologics

Afternoon Session : Why Biopharma CDMO Companies Must Pursue Long-Term Sustainability

- Team leader at GlO Team, SamsungBiologics
- MBA, University of Southern California
- B.S. in Mechenichal Engineering, University of California at Irvine

Hak Bae Choi CEO, Haplnscience

IR Session

- Co-CEO, Kolmar Korea, President of Pharmaceutical Affairs
- CEO, C&C Research Laboratories at JW Pharmaceutical
- Director, Global Business Development&Sales, JW Pharmaceutical

Jade Kim CEO, Inventage Lab

IR Session

- Chief, Clinical development team, BCWorld Pharm
- Manager, Academic team, Seegene
- R&D Center, Kwangdong Pharmaceutical
- Ph.D in Biocemistry, Kyungpook National University
- Masters in Biochemestry, Hanyang University Medical School

Byong Hwa Lee CEO, Toolgene

IR Session

- CEO, MGMED
- CEO, Macrogen
- Korea Long-term Credit Bank, KB Bank
- Yonsei University

Chang-Hwan Kim Executive VP, ProtiumScience

IR Session

- Process Development Division, Division Head, TiumBio
- USP Development Team, Team Leader & Project Leader, Genexine
- USP Development Team, SME (Subject Matter Expert), SAMSUNG BIOEPIS
- Bio Team 2, Project Leader, Hanmi Pharm

Seung Jae Lee CEO, C&L Therapeutics

IR Session

- Business Development, Alteogen
- Researcher, Seoul National University Department of Physics
- Researcher, Howard Hughes Medical Research Institute (HHMI)
- Researcher, New York Cold Spring Harbor Laboratory (CSHL)
- Researcher, Texas State University of Medicine Southwestern Medical Center (UTSW)
- Ph.D. in structural biochemistry

Tea Jin Kang CEO, Renhaim Therapeutics

IR Session

- EyeGene
- Novotech Asia Korea
- SK Discovery(SK Chemicals)
- Masters in Pharmacy, Yonsei University

Dong Sik Ham Director, Advanced Biopharmaceuticals, SCM Lifescience

IR Session

- Member of policy committee, Council for Advanced Regenerative Medicine
- Research Professor, The Catholic University of Korea St. Mary’s hospital
- Ph.D. in Cell Biology, Catholic University
- M.S. in Neuroscience and Technology, Ajou University
- B.S. in Life Sciences, Ajou University

Chae Ok Yun CEO, Genemedicine

IR Session

- Professor, Department of Bioengineering, Hanyang University
- Member, The National Academy of Engineering of Korea
- Expert Committee on Gene Therapy, Ministry of Food and Drug Safety
- Ph.D in Molecular Cell Biology, University of Illinois